CLIMB BIO, INC. (CLYM) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $556.55M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-67.00K; Retained Earnings (Accumulated Deficit)USD $-316.95M.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $451.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $157.00K; Retained Earnings (Accumulated Deficit)USD $-303.45M.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $449.76M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $435.00K; Retained Earnings (Accumulated Deficit)USD $-289.73M.
- 2025-09-30: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $448.74M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $469.00K; Retained Earnings (Accumulated Deficit)USD $-272.21M.
CLIMB BIO, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.00K | $556.55M | $-67.00K | $-316.95M | $239.55M | 3 month · $1.48M | (m) |
| 2026-03-31 | $5.00K | $451.37M | $157.00K | $-303.45M | $148.09M | 3 month · $1.60M | (m) |
| 2025-12-31 | $5.00K | $449.76M | $435.00K | $-289.73M | $160.47M | 12 month · $8.05M | (m) |
| 2025-09-30 | $7.00K | $448.74M | $469.00K | $-272.21M | $177.00M | 3 month · $3.98M | (m) |
| 2025-06-30 | $7.00K | $444.76M | $318.00K | $-259.32M | $185.76M | 3 month · $1.01M | (m) |
| 2025-03-31 | $7.00K | $443.75M | $286.00K | $-250.66M | $193.38M | 3 month · $2.02M | (m) |
| 2024-12-31 | $7.00K | $441.73M | $23.00K | $-229.88M | $211.88M | 12 month · $5.56M | (m) |
| 2024-09-30 | $7.00K | $440.03M | $201.00K | $-221.46M | $218.78M | 3 month · $2.92M | (m) |
| 2024-06-30 | $7.00K | $434.83M | $0.00 | $-212.56M | $222.28M | 3 month · $512.00K | (m) |
| 2024-03-31 | $3.00K | $264.06M | $0.00 | $-157.68M | $106.38M | 3 month · $465.00K | (m) |
| 2023-12-31 | $3.00K | $263.58M | $-2.00K | $-155.98M | $107.60M | 12 month · $12.81M | (m) |
| 2023-09-30 | $3.00K | $262.09M | $-11.00K | $-152.34M | $109.74M | 3 month · $656.00K | (m) |
| 2023-06-30 | $3.00K | $260.90M | $-35.00K | $-148.37M | $112.50M | 3 month · $777.00K | (m) |
| 2023-03-31 | $3.00K | $260.10M | $-95.00K | $-143.15M | $116.86M | 3 month · $10.17M | (m) |
| 2022-12-31 | $3.00K | $249.93M | $-358.00K | $-120.86M | $128.72M | 12 month · $6.99M | (m) |
| 2022-09-30 | $3.00K | $248.03M | $-581.00K | $-113.10M | $134.36M | 3 month · $1.78M | (m) |
| 2022-06-30 | $3.00K | $246.25M | $-604.00K | $-103.42M | $142.24M | 3 month · $1.77M | (m) |
| 2022-03-31 | $3.00K | $244.48M | $-521.00K | $-88.82M | $155.14M | 3 month · $1.54M | (m) |
| 2021-12-31 | $3.00K | $242.94M | $-123.00K | $-75.62M | $167.20M | 12 month · $3.74M | (m) |
| 2021-09-30 | $3.00K | $241.75M | $-18.00K | $-65.07M | $176.66M | 3 month · $1.24M | (m) |
| 2021-06-30 | $1.00K | $4.61M | (m) | $-55.46M | $-50.84M | 3 month · $1.05M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-43.18M | 3 month · $297.00K | (m) |
| 2020-12-31 | $1.00K | $3.15M | $0.00 | $-28.14M | $-24.98M | 12 month · $707.00K | 12 month · $-1.50M |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-12.48M | 3 month · $49.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-9.81M | 3 month · $51.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-7.78M | 3 month · $134.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-5.56M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |